Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo.
Pamela J GoodwinRyan J O DowlingMarguerite EnnisBingshu E ChenWendy R ParulekarLois E ShepherdKaren A GelmonTimothy J WhelanJennifer A LigibelDawn L HershmanIngrid A MayerTimothy J HobdayPriya RastogiManuela RabaglioJulie LemieuxAlastair M ThompsonDaniel W ReaVuk StambolicPublished in: JNCI cancer spectrum (2021)
Our observation that metformin reduces CA 15-3 by approximately 6% was corroborated in a large placebo-controlled randomized trial. The clinical implications of this reduction in CA 15-3 will be explored in upcoming efficacy analyses of breast cancer outcomes in MA.32.